Skip to main content

Advertisement

SpringerLink
Log in

Characterizing the willingness to undergo treatment in patients with alopecia areata

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Alopecia areata is an autoimmune disease that results in partial or total balding of the scalp and/or body. Treatments available are minimally effective, have severe side effects, and are often painful. Given these burdens, patients may not feel undergoing treatment is worthwhile. The purpose of this study is to characterize the willingness of patients with alopecia areata to undergo treatment. We found that few patients are willing to undergo treatment at the risk of severe health side effects. The most acceptable form of treatment administration was topical and the least acceptable was injection at the site of hair loss. A majority of patients would only undergo treatment for hair growth that is cosmetically acceptable and the most important site of hair regrowth was the scalp. The willingness to undergo treatment differed significantly by gender, age, time since disease onset, and disease severity. This study offers insight into the preferences of patients with alopecia areata and characteristics that would make treatment widely acceptable. Institutions conducting research on treatment for alopecia areata can use the results of this study to better understand the needs of their target population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Availability of data and materials

Not applicable.

Code availability

SAS was used for all analysis in this study. Code can be provided upon request.

References

  1. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ (1995) Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 70:628–633

    Article  CAS  Google Scholar 

  2. Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR (2014) Lifetime incidence risk of alopecia areata estimated at 2.1 percent by Rochester Epidemiology Project, 1990–2009. J Invest Dermatol 134(4):1141–1142

    Article  CAS  Google Scholar 

  3. Villasante Fricke AC, Miteva M (2015) Epidemiology and burden of alopecia areata: a systematic review. Clin Cosmet Investig Dermatol 8:397–403

    PubMed  PubMed Central  Google Scholar 

  4. FAQ’s. National alopecia areata foundation. https://www.naaf.org/faqs. Accessed Jan 31, 2020.

  5. Alkhalifah A (2010) Alopecia areata update part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 62(2):177–188

    Article  CAS  Google Scholar 

  6. Tucker P (2009) Bald is beautiful? The psychosocial impact of alopecia areata. J Health Psychol 14(1):142–151

    Article  Google Scholar 

  7. Schmidt S (2003) Female alopecia: the mediating effect of attachment patterns on changes in subjective health indicators. Br J Dermatol 148:1205–1211

    Article  CAS  Google Scholar 

  8. Colón EA, Popkin MK, Callies AL, Dessert NJ, Hordinsky MK (1991) Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 32(3):245–251

    Article  Google Scholar 

  9. Kӧkҫam I, Akyar N, Saral Y, Oǧuzhanoǧlu NK (1999) Psychosomatic symptoms in patients with alopecia areata and vitiligo. Tr J of Medical Sciences 29:471–473

    Google Scholar 

  10. Welsh N, Guy A (2009) The lived experience of alopecia areata: a qualitative study. Body Image 6(3):194–200

    Article  Google Scholar 

  11. Hunt N, McHale S (2005) Reported experiences of persons with alopecia areata. J Loss Trauma 10:33–50

    Article  Google Scholar 

  12. Firooz A, Ghazisaidi B (2005) Concepts of patients with alopecia areata about their disease. BMC Dermatol 5:1

    Article  Google Scholar 

  13. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J (2010) Alopecia areata update: part II. Treatment. J Am Acad Dermatol 62(2):191–202

    Article  CAS  Google Scholar 

  14. Ranawaka RR (2014) An observational study of alopecia areata in Sri Lanka adult patients. Ceylon Med J 59:128–131

    Article  CAS  Google Scholar 

  15. Amirnia M, Mahmoudi SS, Karkon-Shayan F et al (2015) Comparative study of intralesional steroid injection and cryotherapy in alopecia areata. Niger Med J 56(4):249–252

    Article  Google Scholar 

  16. Chang KH, Rojhirunsakool S, Goldberg LJ (2009) Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol 8(10):909–912

    PubMed  Google Scholar 

  17. Charuwichitratana S, Wattanakrai P, Tanrattanakorn S (2000) Randomized double-blind placebo-controlled trial in the treatment of alopecia areata with 0.25% desoximetasone cream. Arch Dermatol 136:1276–1277

    Article  CAS  Google Scholar 

  18. Pascher F, Kurtin S, Andrade R (1970) Assay of 0.2% fluocinolone acetonide cream for alopecia areata and totalis. Dermatology 141:193–202

    Article  CAS  Google Scholar 

  19. Crispin MK, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1(15):1–10

    Google Scholar 

  20. Liu LY, Craiglow BG, Feng D, King BA (2016) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76(1):22–28

    Article  Google Scholar 

  21. Castelo-Soccio L (2017) Experience with oral tofacitinib in 8 adolescent patients with Alopecia universalis. J Am Acad Dermatol 76(4):754–755

    Article  Google Scholar 

  22. Reid EE, Haley AC, Borovicka JH et al (2012) Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. J Am Acad Dermatol 66(3):e97-102

    Article  Google Scholar 

  23. Textor J, Zander B, Gilthorpe MK, Liskiewicz M, Ellison GTH (2016) Robust causal inference using directed acyclic graphs: the R package ‘dagitty.’ Int J Epidemiol 45(6):1887–1894

    PubMed  Google Scholar 

  24. Ng KF, Norazirah MN, Mazlin MB, Adawiyah J, Shamsul AS (2017) Psychological impact, self-perception and the contributing factors in patients with androgenetic alopecia. J Cosmo Trichol 3:3

    Google Scholar 

  25. Weitz R (2001) Women and their hair seeking power through resistance and accommodation. Gend Soc 15(5):667–686

    Article  Google Scholar 

  26. Dixson BJW, Rantala MJ (2016) The role of facial and body hair distribution in women’s judgement of men’s sexual attractiveness. Arch Sex Behav 45:877–889

    Article  Google Scholar 

Download references

Acknowledgements

Supported by a Research Award from the National Alopecia Areata Foundation.

Funding

Funding was provided by the National Alopecia Areata Foundation.

Author information

Authors and Affiliations

  1. School of Medicine, Department of Public Health Sciences, University of Virginia, 200 Jeanette Lancaster Way, Charlottesville, VA, 22903, USA

    Lauren F. O’Connor & Kristen M. Wells

Authors
  1. Lauren F. O’Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kristen M. Wells
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lauren F. O’Connor.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 25 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Connor, L.F., Wells, K.M. Characterizing the willingness to undergo treatment in patients with alopecia areata. Arch Dermatol Res 314, 749–757 (2022). https://doi.org/10.1007/s00403-021-02286-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-021-02286-z

Keywords

Search

Navigation